SRC and neuroblastoma: Based on the observed TACR1 expression and previous reports of TACR1 mitogenic properties in other tumor entities we hypothesized that TACR1 activity might exhibit mitogenic functions in a subset of neuroblastoma cells through activation of SRC and other downstream targets and that pharmaceutically inhibiting TACR1 could be a therapeutic option in these cells.